Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valemetostat Tosylate in Relapsed/Refractory Adult T-cell Leukemia/Lymphoma
NCT04102150Phase 2Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Nov 2019
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of valemetostat in adult T-cell leukemia-lymphoma (ATLL), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Overall response rate up to 5 years. Started Nov 2019; status: completed.
02
Drugs
valemetostat
03
Conditions
adult T-cell leukemia-lymphoma (ATLL)
Beyond the preview
Go deeper on NCT04102150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04102150.